Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Leisha Kopp
To 1000L and beyond: streamlining AAV manufacturing with transfection complex stabilization
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format. Unlock easier, more efficient AAV manufacturing scale-up with a novel approach to transfection. This webinar introduces an approach designed to help process development and manufacturing teams overcome two key limitations during scale-up: short transfection complex stability and the high volume of transfection reagents required at large scale.
How to build an AAV platform that produces higher titers and percent full capsids
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format. With the approval of several gene therapies last year and more than fifteen programs already in the queue for 2024, there is an increasing need for more effective, scalable, and cost-conscious manufacturing of recombinant AAV and lentivirus (LV).
How to increase AAV production with a novel enhancer designed for use with any transfection reagent in any suspension HEK cell
Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format. With the success of cell and gene therapies and exponentially increasing demand, the second wave of viral vector manufacturing is focused on large-scale suspension cell culture.
Improving AAV and LV upstream manufacturing using cGMP lipid polymer nanocomplexes (LPNCs)
Thursday, June 1, 08:00 PST, 11:00 EST, 16:00 GMT, 17:00 CET Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format. With success of cell and gene therapies and exponentially increasing demand, the second wave of viral vector manufacturing is focused on large-scale suspension cell culture and/or adherent cell culture within intensified fixed bed bioreactors.
Transfection innovation for large-scale AAV & LV: considerations for process development through commercial manufacturing
Cell & Gene Therapy Insights 2022; 8(9), 1169–1176 DOI: 10.18609/cgti.2022.174 GMP-compliant nucleic acid delivery to HEK293 cells is often a critical first step in the manufacture of advanced therapies utilizing recombinant adeno-associated virus (AAV) or lentivirus (LV) to facilitate delivery of a therapeutic transgene to patients. Accordingly, the need for safe and reproducible large-scale viral vector manufacture processes has never been greater.
Smart and scalable transfection platforms for start-to-finish AAV and LV development
Thursday September 1st 2022 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format. GMP-compliant plasmid delivery to HEK 293 cells is a critical first step in generating recombinant adeno-associated virus (AAV) and lentivirus (LV) for advanced therapies requiring delivery of a therapeutic transgene to patients.
Complete system for AAV production for clinical production: Part 1 Upstream
AAV manufacturing challenges have been extensively discussed for several years. With a limited biological understanding of recombinant vector production and the limited amount of time developers have to optimize, scale, and qualify their manufacturing process, flexible solutions that can adapt to several vectors, cell lines, or facilities are needed. Thermo Fisher Scientific has answered this need with systems, reagents, and equipment that meet the needs of this fast-moving industry.
Optimizing mRNA purification conditions by using a Design of Experiments approach
Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format. To support the development of mRNA-based therapies we have developed a platform chromatography solution for the purification of mRNA. The POROS™ Oligo dT(25) affinity resin helps to address the selectivity and capacity requirements for the large-scale manufacturing of mRNA used in vaccine and gene therapy applications.
Key considerations for maximizing LV and AAV production in transient transfection workflows
As you are already a member of Immuno-Oncology Insights (also from Bioinsights), all you need to do is tick the box below. I would like to become a member of Cell & Gene Therapy
Key considerations for maximizing LV and AAV production in transient transfection workflows
Welcome back, please log in to access our articles, interviews, webinars and more Welcome back, please log in to access our articles, interviews, webinars and more If you would also like to sign up to access articles from Immuno-Oncology Insights - one of the other great titles from Bioinsights, please tick the box below.
Addressing the challenges of purification & quality control in gene therapy
Dr. Akash Bhattacharya Senior Application Engineer, Beckman Coulter Life Sciences Akash Bhattacharya graduated from Presidency College, India with a major in Physics and went on to a Masters’ in Physics at the Indian Institute of Science where he worked on Quantum Computing. He then moved for doctoral studies in Biophysics to the University of Michigan, Ann Arbor where he joined the lab of Prof.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Leisha
Contact Leisha, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack